<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405756</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-015</org_study_id>
    <secondary_id>2006-001865-41</secondary_id>
    <nct_id>NCT00405756</nct_id>
  </id_info>
  <brief_title>A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.</brief_title>
  <official_title>A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (RevlimidÂ®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years Of Age Or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lenalidomide is safe and effective in the
      treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three phases for the study as originally defined and as represented in the results of 11
      May 2010 are:

      Double-blind Treatment Phase: Induction Melphalan/prednisone and lenalidomide 10 mg (MPR) (2
      treatment arms), or melphalan/prednisone and placebo (MPp) (1 treatment arm) for up to 9
      cycles. If disease progression, subjects have the option to enter into the Open-Label
      Extension Phase. There is also an option to enter into the Follow-Up Phase. If the disease
      has not progressed, subject can continue on blinded therapy into Maintenance.

      Double-blind Treatment Phase: Maintenance One MPR treatment arm (MPR+R) will continue taking
      lenalidomide 10 mg in Maintenance. The other MPR treatment arm (MPR+p) will take placebo in
      Maintenance. The MP p treatment arm will take placebo in Maintenance (MPp+p). If disease
      progression, subjects have the option to enter the Open-Label Extension Phase to obtain
      treatment with lenalidomide, or to enter into the Follow-up Phase.

      Open-label Extension Phase:

      Treatment consists of oral lenalidomide (up to 25 mg) with or without dexamethasone until
      disease progression or treatment is discontinued for any reason until all study subjects are
      followed for at least 5 years from the date of randomization or have died. Subjects who
      discontinue from the Open-Label Extension Phase prior to completing a total of 5 years in the
      study will enter the Follow-up Phase.

      Follow-up Phase:

      Subjects are followed for overall survival and subsequent anti-myeloma treatment regimens
      until all subjects in this study are followed for at least 5 years from randomization or have
      died.

      The pre-planned interim analysis for the Independent Data Monitoring Committee (IDMC) showed
      that the difference in progression-free survival (PFS) between treatment arms MPR+R and MPp+p
      (the defined primary comparative analysis for this study) surpassed the pre-specified
      O'Brien-Fleming boundary for superiority. The IDMC recommended the release of this
      information to the sponsor and also recommended that all patient and physician study
      participants receive information concerning the full findings of the MM-015 interim analysis.
      Therefore, due to these recommendations from the IDMC, treatment-arm codes were sent to the
      clinical trial centers to unblind the treatment arms of their study subjects once the amended
      protocol was reviewed and approved by the respective country Health Authorities and Ethics
      Committees. Subject participation in the MM-015 study continued after unblinding to obtain
      long-term data for all study endpoints, including overall survival.

      When the study was unblinded, subjects still on protocol therapy had completed the
      Double-Blind Induction, and were on monotherapy in Double-Blind Maintenance. Subjects in arm
      MPR+R continued their monotherapy on lenalidomide. Subjects in arms MPR+p and MPp+p
      discontinued their placebo monotherapy and went into an observation period in which no
      antimyeloma therapy was taken. If disease progressed for any subject, the investigator had
      the option of entering the subject in Open Label Extension Phase to receive lenalidomide
      therapy (up to 25 mg daily) or the Follow-up Phase. All subjects were to be followed for at
      least 5 years from the start of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)</measure>
    <time_frame>up to 165 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)</measure>
    <time_frame>Approximately week 37 (start of cycle 10) to week 165</time_frame>
    <description>Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.
PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Overall Survival (OS)</measure>
    <time_frame>up to 177 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)</measure>
    <time_frame>up to 165 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period</measure>
    <time_frame>Up to 165 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response</measure>
    <time_frame>Up to 66 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)</measure>
    <time_frame>Up to 149 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates for Time to Next Antimyeloma Therapy</measure>
    <time_frame>Up to 168 weeks</time_frame>
    <description>Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period</measure>
    <time_frame>Up to 169 weeks (Double-blind therapy period plus 4 weeks)</time_frame>
    <description>Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale</measure>
    <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
    <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPp+p</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide: Double-blind Induction</intervention_name>
    <description>Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.</description>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_label>MPR+p</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.</description>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_label>MPp+p</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.</description>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_label>MPp+p</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.
Double-blind maintenance: at the investigator's discretion</description>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_label>MPp+p</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.
Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.</description>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_label>MPp+p</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide: Double-blind Maintenance</intervention_name>
    <description>Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.</description>
    <arm_group_label>MPR+R</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide: Open-label</intervention_name>
    <description>Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.</description>
    <arm_group_label>MPR+R</arm_group_label>
    <arm_group_label>MPR+p</arm_group_label>
    <arm_group_label>MPp+p</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Must understand and voluntarily sign an informed consent form

          2. Age greater than or equal to 65 years at the time of signing the informed consent

          3. Newly diagnosed with symptomatic multiple myeloma as defined by the 3 criteria below:

        MM diagnostic criteria (all of next 3 required)

          1. Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or
             presence of a biopsy-proven plasmacytoma

          2. Monoclonal protein present in the serum and/or urine

          3. Myeloma-related organ dysfunction (at least one of the following) [C] Calcium
             elevation in the blood (serum calcium &gt;10.5mg/dl or upper limit of normal) [R] Renal
             insufficiency (serum creatinine &gt;2mg/dl) [A] Anemia (hemoglobin &lt;10g/dl or 2g &lt;
             normal) [B] Lytic bone lesions or osteoporosis AND have measurable disease as defined
             by the following; IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level
             greater than or equal to 1.0 g/dL or urine M-protein level greater than or equal to
             200 mg/24 hours IgA multiple myeloma: Serum M-protein level greater than or equal to
             0.5 g/dL or urine M-protein level greater than or equal to 200 mg/24 hours IgD
             multiple myeloma: Serum M-protein level greater than or equal to 0.05 g/dL or urine
             M-protein level greater than or equal to 200 mg/24 hours Light chain multiple myeloma:
             Serum M-protein level greater than or equal to 1.0 g/dL or urine M-protein level
             greater than or equal to 200 mg/24 hours IgM multiple myeloma (IgM M-protein plus
             lytic bone disease documented by skeletal survey plain films): Serum M-protein level
             greater than or equal to 1.0g/dL or urine M-protein level greater than or equal to
             200mg/24hours

          4. Karnofsky performance status greater than or equal to 60%.

          5. Able to adhere to the study visit schedule and other protocol requirements.

          6. Women of Childbearing potential (WCBP) must:

             a. Have a negative medically supervised pregnancy test prior to the start of study
             therapy. She must agree to ongoing pregnancy testing during the course of the study,
             and after end of study therapy. This applies even if the subject practices and
             continues sexual abstinence.

             b Either commit to continued abstinence from heterosexual intercourse (which must be
             reviewed on a monthly basis) or agree to use, and be able to comply with, effective
             contraception without interruption, 28 days prior to starting study drug, during the
             study therapy (including dose interruptions), and for 28 days after discontinuation of
             study therapy.

          7. Males Subjects must:

               1. Agree to use a condom during sexual contact with a WCBP, even if they have had a
                  vasectomy, throughout study drug therapy, during any dose interruption and after
                  the cessation of study therapy.

               2. Agree to not donate semen during study drug therapy and for a period after end of
                  study drug therapy.

          8. All subjects must

               1. Have an understanding that the study drug could have potential teratogenic risk.

               2. Agree to abstain from donating blood while taking study drug therapy and
                  following discontinuation of study drug therapy.

               3. Agree not to share study medication with another person.

               4. All patients must be counseled about pregnancy precautions and risks of fetal
                  exposure.

        Female Subjects:

        Females of childbearing potential (FCBP) with regular cycles must agree to have pregnancy
        tests weekly for the first 28 days of study participation and then every 28 days while on
        study, at study discontinuation, and at day 28 following discontinuation from the study. If
        menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28
        days and then every 14 days while on study, at study discontinuation, and at days 14 and 28
        following discontinuation from the study.

        In addition to the required pregnancy testing, the Investigator must confirm with FCBP that
        she is continuing to use two reliable methods of birth control at each visit. Counseling
        about pregnancy precautions and the potential risks of fetal exposure must be conducted at
        a minimum of every 28 days. During counseling, subjects must be reminded to not share study
        drug and to not donate blood.

        Pregnancy testing and counseling must be performed if a subject misses her period or if her
        pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be
        discontinued during this evaluation.

        Females must agree to abstain from breastfeeding during study participation and for at
        least 28 days after the discontinuation from the study.

        Male Subjects:

        Counseling about the requirement for latex condom use during sexual contact with females of
        childbearing potential and the potential risks of fetal exposure must be conducted at a
        minimum of every 28 days. During counseling, subjects must be reminded to not share study
        drug and to not donate blood, sperm, or semen.

        If pregnancy or a positive pregnancy test does occur in a study subject or the partner of a
        study subject during study participation, study drug must be immediately discontinued.

        Exclusion Criteria

          1. Previous treatment with antimyeloma therapy (does not include radiotherapy,
             bisphosphonates, or a single short course of steroid [i.e., less than or equal to the
             equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid
             treatment must not have been given within 28 days [4 weeks] of randomization]).

          2. Any serious medical condition, including the presence of laboratory abnormalities,
             which places the subject at an unacceptable risk if he or she participates in this
             study or confounds experimental the ability to interpret data from the study.

          3. Pregnant or lactating females.

          4. Radiotherapy within 14 days (2 weeks) of randomization.

          5. Plasmapheresis within 28 days (4 weeks) of randomization.

          6. Any of the following laboratory abnormalities:

             Absolute neutrophil count (ANC) &lt; 1,500 cells/mL (1.5*10^9/L) Platelet count &lt; 75,000
             cells/uL (75*10^9/L) for subjects in whom &lt; 50% of bone marrow nucleated cells are
             plasma cells; but platelet count &lt;30,000/uL for subjects in whom &gt;= 50% of bone marrow
             nucleated cells are plasma cells Haemoglobin &lt; 8.0 g/dL (80 g/L) Serum creatinine &gt;
             2.5 mg/dL (221 Âµmol/L) Serum aspartate aminotransferase (SGOT/AST) or alanine
             aminotransferase (SGPT/ALT) &gt; 3.0 times upper limit of normal (ULN)

          7. Prior history of malignancies, other than multiple myeloma, unless the subject has
             been free of the disease for greater than or equal to 3 years.

             Exceptions include the following:

             Basal cell carcinoma of the skin Squamous cell carcinoma of the skin Carcinoma in situ
             of the cervix Carcinoma in situ of the breast Incidental histologic finding of
             prostate cancer (TNM Classification of Malignant Tumours (TNM) stage of T1a or T1b)

          8. Neuropathy of &gt;= grade 2 severity.

          9. Known human immunodeficiency virus (HIV) positivity or active infectious hepatitis,
             type A, B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Palumbo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Oncology Clinics of Australia, Level 5, Mater Medical Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Institute of Medical and Veterinary Science</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology</name>
      <address>
        <city>East Melbourne</city>
        <zip>3006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Salzburg St Johanns Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <zip>246 042</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 9</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan Brugge Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>128 081</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ¦matologisk afd. B Aalborg Sygehus Syd</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinsk afd. Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - HÃ´pital Dupuytren</name>
      <address>
        <city>Limoges Cedex 1</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier- Hopital Lapeyronie</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - HÃ´pitaux de Paris AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>TSA 40031-31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd M.Zodelava Hematology Centre</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusiology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II der Charite Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt-UniversitÃ¤t Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinik A</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>47589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik - Abteilung II</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II des Universitatsklinikums Wurzburg</name>
      <address>
        <city>WÃ¼rzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. GENNIMATAS General Hospital of Athens Department of Hematolgosy</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Air Force Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Directorate Haematology Oncology Service St. James Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midlands Regional</name>
      <address>
        <city>Tullamore / Co Offally</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Institute, Hemato-Oncology Division,Davidoff Cancer Center, Rabin MC Beilinson Hospital</name>
      <address>
        <city>Petch Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartmento Oncologico Struttura Complessa di ematlologiaA.O. Ospedale Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo Universita Di Pavia</name>
      <address>
        <city>Pavia 2</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Di Ematologia Ospedale Cattedra di Ematologia</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I, Universita La Sapienzadi Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Onco-Ematologia</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD/3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Samodzielny Publiczny Szpital Kliniczny Akademii</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Internal Diseases University of Medicine</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Kliniki Hematologii</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Medyczny w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University School of Medicine</name>
      <address>
        <city>Lublin</city>
        <zip>20-290</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademia Medyczna w Warszawie Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burdenko Central Military Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl</name>
      <address>
        <city>Moscow</city>
        <zip>115678</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research Institute n.a. Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Center RAMS</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitaro Puerta del MarServicio de Hematologia</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princessa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken</name>
      <address>
        <city>Boras</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinska kliniken</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitatsSpital ZurichKlinik fur Onkologie</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical School</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Center</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk City Clinical Hospital 4</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urgent and Recovery Surgery</name>
      <address>
        <city>Donetsk</city>
        <zip>83047</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusiology of the UAMS Department of blood diseases</name>
      <address>
        <city>Kiev</city>
        <zip>04060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine</name>
      <address>
        <city>Lviv 79044</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhitomir Regional Clinical Hospital</name>
      <address>
        <city>Zhitomir</city>
        <zip>10003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Aidrie</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 9TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie NHS Trust Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Dimopoulos MA, Delforge M, HÃ¡jek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013 May;98(5):784-8. doi: 10.3324/haematol.2012.074534. Epub 2012 Dec 14.</citation>
    <PMID>23242595</PMID>
  </results_reference>
  <results_reference>
    <citation>Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-JÄdrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, BladÃ© J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.</citation>
    <PMID>22571200</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <results_first_submitted>April 16, 2012</results_first_submitted>
  <results_first_submitted_qc>April 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2012</results_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly Diagnosed Multiple Myeloma</keyword>
  <keyword>Celgene</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data represents a May 11, 2010 data cut-off. The study is ongoing.</recruitment_details>
      <pre_assignment_details>Of the 606 subjects screened for this study, 147 failed screening. Reasons for screen failures included: laboratory values not met (45 subjects); diagnostic criteria for measurable multiple myeloma not met (30 subjects); other inclusion/exclusion criteria not met (30 subjects); subject withdrawal of consent (14 subjects); and other (28 subjects).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MPR+R</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="P2">
          <title>MPR+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="P3">
          <title>MPp+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152">Intent to treat population of all randomized participants</participants>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="150">Participants who took at least one dose of study drug.</participants>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Double-blind Treatment Period had no defined completion.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing in Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants continue until disease progression or other reason for discontinuing.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing in Open Label Period</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75">66 participants from Double-blind and 9 from the Open Label Extension</participants>
                <participants group_id="P2" count="90">65 participants from the Double-blind and 25 from the Open Label Extension</participants>
                <participants group_id="P3" count="88">52 participants from the Double-blind and 36 from the Open Label Extension</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing in Follow-up Period</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MPR+R</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="B2">
          <title>MPR+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="B3">
          <title>MPp+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="154"/>
            <count group_id="B4" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="5.33"/>
                    <measurement group_id="B2" value="72.1" spread="5.20"/>
                    <measurement group_id="B3" value="72.0" spread="5.26"/>
                    <measurement group_id="B4" value="72.0" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian / Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="14.77"/>
                    <measurement group_id="B2" value="72.0" spread="12.79"/>
                    <measurement group_id="B3" value="72.1" spread="15.20"/>
                    <measurement group_id="B4" value="72.5" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.8" spread="9.81"/>
                    <measurement group_id="B2" value="165.3" spread="9.33"/>
                    <measurement group_id="B3" value="165.7" spread="9.79"/>
                    <measurement group_id="B4" value="165.3" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.9" spread="17.71"/>
                    <measurement group_id="B2" value="135.5" spread="18.60"/>
                    <measurement group_id="B3" value="136.4" spread="20.13"/>
                    <measurement group_id="B4" value="135.3" spread="18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.5" spread="9.53"/>
                    <measurement group_id="B2" value="77.4" spread="9.99"/>
                    <measurement group_id="B3" value="78.8" spread="10.40"/>
                    <measurement group_id="B4" value="78.2" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature</title>
          <units>degrees centigrade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="0.41"/>
                    <measurement group_id="B2" value="36.5" spread="0.38"/>
                    <measurement group_id="B3" value="36.5" spread="0.40"/>
                    <measurement group_id="B4" value="36.5" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="9.77"/>
                    <measurement group_id="B2" value="77.3" spread="10.50"/>
                    <measurement group_id="B3" value="76.3" spread="10.80"/>
                    <measurement group_id="B4" value="76.5" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Scale</title>
          <description>Karnofsky Performance Scale classifies patients according to their functional impairment. Scores range from 0-100, the lower the score, the greater the impairment and worse prospect of survival for most serious illnesses.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.1" spread="11.95"/>
                    <measurement group_id="B2" value="82.2" spread="11.71"/>
                    <measurement group_id="B3" value="84.0" spread="11.46"/>
                    <measurement group_id="B4" value="82.4" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Staging System (ISS)</title>
          <description>ISS form multiple myeloma divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Higher stages represent more advanced disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=60 ml/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;60 ml/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta2 Microglobulin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;5.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=5.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;35 g/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;= 35 g/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive Protein</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;4 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=4 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple Myeloma Subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Immunoglobulin A (IgA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Cells in the Bone Marrow</title>
          <units>percentage of plasma cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="24.79"/>
                    <measurement group_id="B2" value="39.3" spread="25.01"/>
                    <measurement group_id="B3" value="37.9" spread="23.65"/>
                    <measurement group_id="B4" value="39.0" spread="24.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
        <description>Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>up to 165 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
          <description>Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Intent-to-treat population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.1" lower_limit="86.14">Upper limit not estimable because of the number of participants without progressive disease at data cut-off.</measurement>
                    <measurement group_id="O2" value="62.1" lower_limit="56.14" upper_limit="72.14"/>
                    <measurement group_id="O3" value="56.1" lower_limit="52.14" upper_limit="68.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.395</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.278</ci_lower_limit>
            <ci_upper_limit>0.560</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.494</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.347</ci_lower_limit>
            <ci_upper_limit>0.702</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.796</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.589</ci_lower_limit>
            <ci_upper_limit>1.075</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
        <description>Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.
PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>Approximately week 37 (start of cycle 10) to week 165</time_frame>
        <population>Intent to treat (ITT) population of participants in Arms MPR+R and MPR+p who entered maintenance within the Double-blind Treatment Period</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
          <description>Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.
PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Intent to treat (ITT) population of participants in Arms MPR+R and MPR+p who entered maintenance within the Double-blind Treatment Period</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.0" lower_limit="83.29">Upper limit not estimable because of the number of participants without progressive disease at data cut-off.</measurement>
                    <measurement group_id="O2" value="32.3" lower_limit="23.57" upper_limit="52.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>P-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.340</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.214</ci_lower_limit>
            <ci_upper_limit>0.541</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Overall Survival (OS)</title>
        <description>Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.</description>
        <time_frame>up to 177 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Overall Survival (OS)</title>
          <description>Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.</description>
          <population>Intent to treat population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not able to estimate since few participants died as of the May 11, 2010 cut-off.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="148.43">Not able to estimate since few participants died as of the May 11, 2010 cut-off.</measurement>
                    <measurement group_id="O3" value="NA">Not able to estimate since few participants died as of the May 11, 2010 cut-off.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
        <description>Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>up to 165 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)</title>
          <description>Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Intent to treat population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.1" lower_limit="100.00">Upper limit not estimable because of the number of participants without progressive disease at data cut-off.</measurement>
                    <measurement group_id="O2" value="62.7" lower_limit="57.14" upper_limit="74.14"/>
                    <measurement group_id="O3" value="61.3" lower_limit="52.29" upper_limit="70.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.337</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.231</ci_lower_limit>
            <ci_upper_limit>0.493</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.414</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.284</ci_lower_limit>
            <ci_upper_limit>0.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.223</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.826</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.606</ci_lower_limit>
            <ci_upper_limit>1.125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period</title>
        <description>Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).</description>
        <time_frame>Up to 165 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period</title>
          <description>Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus &gt;=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).</description>
          <population>Intent to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value calculation excludes the category - Response not evaluable (NE)</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-value calculation excludes the category - Response not evaluable (NE)</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value calculation excludes the category - Response not evaluable (NE)</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Based on dichotomized response: 1) CR or PR 2) SD or PD or NE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>5.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on dichotomized response: 1) CR or PR 2) SD or PD or NE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Based on dichotomized response: 1) CR or PR 2) SD or PD or NE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Response</title>
        <description>Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.</description>
        <time_frame>Up to 66 weeks</time_frame>
        <population>Participants who had a partial response (PR) or complete response (CR)</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Response</title>
          <description>Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.</description>
          <population>Participants who had a partial response (PR) or complete response (CR)</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="7.40"/>
                    <measurement group_id="O2" value="9.3" spread="6.55"/>
                    <measurement group_id="O3" value="16.2" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)</title>
        <description>Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>Up to 149 weeks</time_frame>
        <population>Population: Participants who achieved a partial response (PR) or complete response (CR).</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)</title>
          <description>Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.
PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Population: Participants who achieved a partial response (PR) or complete response (CR).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" lower_limit="96.00">Upper limit not estimable because of the number of participants without progressive disease at data cut-off.</measurement>
                    <measurement group_id="O2" value="56.1" lower_limit="52.14" upper_limit="64.29"/>
                    <measurement group_id="O3" value="55.4" lower_limit="44.14" upper_limit="76.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.348</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.228</ci_lower_limit>
            <ci_upper_limit>0.531</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.419</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.281</ci_lower_limit>
            <ci_upper_limit>0.623</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.825</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.571</ci_lower_limit>
            <ci_upper_limit>1.191</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates for Time to Next Antimyeloma Therapy</title>
        <description>Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
        <time_frame>Up to 168 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates for Time to Next Antimyeloma Therapy</title>
          <description>Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
          <population>Intent to treat population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" lower_limit="99.86">Upper limit not estimable because of the number of participants who had not started a non-protocol anti-myeloma therapy at data cut-off.</measurement>
                    <measurement group_id="O2" value="66.1" lower_limit="60.14" upper_limit="76.00"/>
                    <measurement group_id="O3" value="66.3" lower_limit="61.14" upper_limit="72.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.404</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.296</ci_lower_limit>
            <ci_upper_limit>0.553</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.363</ci_lower_limit>
            <ci_upper_limit>0.688</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <p_value_desc>The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.827</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.630</ci_lower_limit>
            <ci_upper_limit>1.085</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period</title>
        <description>Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.</description>
        <time_frame>Up to 169 weeks (Double-blind therapy period plus 4 weeks)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period</title>
          <description>Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=1 adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 CTCAE grade 3-4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 CTCAE grade 5 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 serious AE (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE related to Lenaldomide/Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE related to Melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1AE related to Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 3-4 AE related to Lenaldomide/Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 3-4 AE related to Melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 3-4 AE related to Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 5 AE related to Lenalidomide/Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 5 AE related to Melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Grade 5 AE related to Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 SAE related to Lenalidomide/Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 SAE related to Melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 SAE related to Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Lenalidomide/Placebo withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Melphalan withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Prednisone withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Lenalidomide/Plac dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Melphalan dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Prednisone dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Lenalidomide/Plac dose interrupt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Melphalan dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE leading to Prednisone dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=114,121,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="26.13"/>
                    <measurement group_id="O2" value="5.6" spread="18.86"/>
                    <measurement group_id="O3" value="6.1" spread="19.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=96,108,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="24.95"/>
                    <measurement group_id="O2" value="8.1" spread="22.48"/>
                    <measurement group_id="O3" value="4.2" spread="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=84,86,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="25.33"/>
                    <measurement group_id="O2" value="8.8" spread="24.70"/>
                    <measurement group_id="O3" value="6.2" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=70,70,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="28.32"/>
                    <measurement group_id="O2" value="8.8" spread="24.02"/>
                    <measurement group_id="O3" value="5.4" spread="22.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=61,50,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="25.28"/>
                    <measurement group_id="O2" value="7.2" spread="26.29"/>
                    <measurement group_id="O3" value="8.1" spread="25.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=120,127,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="23.72"/>
                    <measurement group_id="O2" value="3.3" spread="21.64"/>
                    <measurement group_id="O3" value="4.5" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=100,112,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="22.71"/>
                    <measurement group_id="O2" value="8.1" spread="20.54"/>
                    <measurement group_id="O3" value="2.7" spread="23.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=88,95,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="22.75"/>
                    <measurement group_id="O2" value="8.5" spread="25.62"/>
                    <measurement group_id="O3" value="5.1" spread="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=75,74,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="24.04"/>
                    <measurement group_id="O2" value="9.7" spread="25.39"/>
                    <measurement group_id="O3" value="3.3" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="25.00"/>
                    <measurement group_id="O2" value="7.6" spread="22.66"/>
                    <measurement group_id="O3" value="1.1" spread="19.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=119,127,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="33.18"/>
                    <measurement group_id="O2" value="3.0" spread="30.75"/>
                    <measurement group_id="O3" value="7.4" spread="26.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=99,112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="35.57"/>
                    <measurement group_id="O2" value="8.0" spread="32.42"/>
                    <measurement group_id="O3" value="6.9" spread="31.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=86,95,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="35.76"/>
                    <measurement group_id="O2" value="7.5" spread="36.29"/>
                    <measurement group_id="O3" value="5.6" spread="31.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=74,74,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="40.36"/>
                    <measurement group_id="O2" value="11.7" spread="33.42"/>
                    <measurement group_id="O3" value="5.7" spread="30.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="40.09"/>
                    <measurement group_id="O2" value="8.5" spread="34.22"/>
                    <measurement group_id="O3" value="7.1" spread="31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=115,125,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="25.00"/>
                    <measurement group_id="O2" value="2.7" spread="22.59"/>
                    <measurement group_id="O3" value="6.8" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=98,111,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="24.94"/>
                    <measurement group_id="O2" value="4.2" spread="20.38"/>
                    <measurement group_id="O3" value="5.0" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=86,92,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="23.28"/>
                    <measurement group_id="O2" value="1.6" spread="22.07"/>
                    <measurement group_id="O3" value="4.7" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=73,73,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="24.59"/>
                    <measurement group_id="O2" value="1.1" spread="21.78"/>
                    <measurement group_id="O3" value="6.6" spread="21.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=63,52,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="23.23"/>
                    <measurement group_id="O2" value="-0.2" spread="21.57"/>
                    <measurement group_id="O3" value="6.9" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=115,125,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="21.51"/>
                    <measurement group_id="O2" value="-2.0" spread="21.33"/>
                    <measurement group_id="O3" value="1.3" spread="16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=98,111,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="22.31"/>
                    <measurement group_id="O2" value="0.1" spread="17.33"/>
                    <measurement group_id="O3" value="0.7" spread="18.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,92,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="22.64"/>
                    <measurement group_id="O2" value="-4.4" spread="19.89"/>
                    <measurement group_id="O3" value="-2.7" spread="20.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=73,73,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="21.34"/>
                    <measurement group_id="O2" value="-3.0" spread="23.78"/>
                    <measurement group_id="O3" value="-1.4" spread="17.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=63,52,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="22.29"/>
                    <measurement group_id="O2" value="-3.5" spread="27.48"/>
                    <measurement group_id="O3" value="-4.0" spread="18.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=115,125,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="35.05"/>
                    <measurement group_id="O2" value="0.3" spread="26.60"/>
                    <measurement group_id="O3" value="6.0" spread="22.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=98,111,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="33.87"/>
                    <measurement group_id="O2" value="4.4" spread="24.48"/>
                    <measurement group_id="O3" value="6.1" spread="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,92,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="34.27"/>
                    <measurement group_id="O2" value="4.5" spread="29.87"/>
                    <measurement group_id="O3" value="4.1" spread="27.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=72,73,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="32.91"/>
                    <measurement group_id="O2" value="7.5" spread="29.80"/>
                    <measurement group_id="O3" value="6.2" spread="27.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=63,52,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="33.35"/>
                    <measurement group_id="O2" value="6.1" spread="30.79"/>
                    <measurement group_id="O3" value="9.8" spread="28.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=120,127,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="25.61"/>
                    <measurement group_id="O2" value="-5.5" spread="24.08"/>
                    <measurement group_id="O3" value="-5.1" spread="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=100,112,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="23.00"/>
                    <measurement group_id="O2" value="-9.5" spread="25.97"/>
                    <measurement group_id="O3" value="-5.7" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,95,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="27.31"/>
                    <measurement group_id="O2" value="-7.5" spread="29.78"/>
                    <measurement group_id="O3" value="-6.9" spread="28.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=74,74,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="26.08"/>
                    <measurement group_id="O2" value="-10.7" spread="30.33"/>
                    <measurement group_id="O3" value="-7.5" spread="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,53,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="26.86"/>
                    <measurement group_id="O2" value="-9.7" spread="28.77"/>
                    <measurement group_id="O3" value="-4.1" spread="26.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=120,127,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="19.40"/>
                    <measurement group_id="O2" value="-1.3" spread="17.14"/>
                    <measurement group_id="O3" value="-0.0" spread="17.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=99,112,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="14.57"/>
                    <measurement group_id="O2" value="-0.7" spread="19.94"/>
                    <measurement group_id="O3" value="0.7" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,95,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="16.75"/>
                    <measurement group_id="O2" value="-1.4" spread="19.40"/>
                    <measurement group_id="O3" value="0.3" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=75,72,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="13.55"/>
                    <measurement group_id="O2" value="-3.0" spread="19.65"/>
                    <measurement group_id="O3" value="-0.4" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,52,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="12.90"/>
                    <measurement group_id="O2" value="-4.2" spread="18.65"/>
                    <measurement group_id="O3" value="-1.3" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=120,127,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="32.76"/>
                    <measurement group_id="O2" value="-13.8" spread="33.60"/>
                    <measurement group_id="O3" value="-13.4" spread="29.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=100,112,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="36.18"/>
                    <measurement group_id="O2" value="-16.5" spread="33.45"/>
                    <measurement group_id="O3" value="-11.5" spread="33.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=88,95,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="34.78"/>
                    <measurement group_id="O2" value="-15.6" spread="35.30"/>
                    <measurement group_id="O3" value="-9.8" spread="31.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=74,74,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="40.48"/>
                    <measurement group_id="O2" value="-14.9" spread="33.28"/>
                    <measurement group_id="O3" value="-12.1" spread="27.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.3" spread="33.92"/>
                    <measurement group_id="O2" value="-11.0" spread="33.00"/>
                    <measurement group_id="O3" value="-12.2" spread="29.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=117,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="29.74"/>
                    <measurement group_id="O2" value="-6.4" spread="32.04"/>
                    <measurement group_id="O3" value="-0.0" spread="23.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=100,110,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="28.18"/>
                    <measurement group_id="O2" value="-8.5" spread="32.07"/>
                    <measurement group_id="O3" value="2.1" spread="20.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=86,93,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="30.60"/>
                    <measurement group_id="O2" value="-4.3" spread="35.87"/>
                    <measurement group_id="O3" value="3.8" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=73,73,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="30.26"/>
                    <measurement group_id="O2" value="-2.3" spread="30.60"/>
                    <measurement group_id="O3" value="-0.0" spread="22.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=62,53,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="29.39"/>
                    <measurement group_id="O2" value="-6.3" spread="32.07"/>
                    <measurement group_id="O3" value="1.6" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=118,124,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="33.56"/>
                    <measurement group_id="O2" value="-1.6" spread="31.77"/>
                    <measurement group_id="O3" value="-5.0" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=100,109,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="29.76"/>
                    <measurement group_id="O2" value="-6.4" spread="27.02"/>
                    <measurement group_id="O3" value="-5.7" spread="32.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,94,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="28.99"/>
                    <measurement group_id="O2" value="-2.5" spread="25.04"/>
                    <measurement group_id="O3" value="-1.7" spread="32.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=75,73,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="29.86"/>
                    <measurement group_id="O2" value="0.9" spread="29.38"/>
                    <measurement group_id="O3" value="-6.8" spread="29.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="32.46"/>
                    <measurement group_id="O2" value="-0.6" spread="32.36"/>
                    <measurement group_id="O3" value="-3.7" spread="31.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=119,125,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="36.54"/>
                    <measurement group_id="O2" value="1.9" spread="34.73"/>
                    <measurement group_id="O3" value="-5.6" spread="25.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=99,111,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="33.64"/>
                    <measurement group_id="O2" value="-5.7" spread="31.75"/>
                    <measurement group_id="O3" value="-5.7" spread="27.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,93,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="33.15"/>
                    <measurement group_id="O2" value="-5.4" spread="29.20"/>
                    <measurement group_id="O3" value="-8.0" spread="29.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=75,72,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="36.23"/>
                    <measurement group_id="O2" value="-8.8" spread="30.13"/>
                    <measurement group_id="O3" value="-4.8" spread="32.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=64,52,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="36.01"/>
                    <measurement group_id="O2" value="-16.0" spread="35.24"/>
                    <measurement group_id="O3" value="-6.4" spread="28.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=114,124,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="34.31"/>
                    <measurement group_id="O2" value="4.8" spread="30.86"/>
                    <measurement group_id="O3" value="-4.9" spread="27.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=96,111,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="36.35"/>
                    <measurement group_id="O2" value="0.6" spread="30.14"/>
                    <measurement group_id="O3" value="-2.7" spread="31.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=86,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="34.88"/>
                    <measurement group_id="O2" value="-1.1" spread="28.43"/>
                    <measurement group_id="O3" value="-1.7" spread="26.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=73,73,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="31.27"/>
                    <measurement group_id="O2" value="-2.7" spread="28.74"/>
                    <measurement group_id="O3" value="-3.3" spread="29.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=63,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="31.36"/>
                    <measurement group_id="O2" value="-5.2" spread="30.82"/>
                    <measurement group_id="O3" value="-2.2" spread="32.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=115,125,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="28.85"/>
                    <measurement group_id="O2" value="1.9" spread="24.06"/>
                    <measurement group_id="O3" value="3.2" spread="25.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=98,109,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="25.54"/>
                    <measurement group_id="O2" value="-1.2" spread="23.09"/>
                    <measurement group_id="O3" value="0.9" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=87,92,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="22.98"/>
                    <measurement group_id="O2" value="1.4" spread="20.91"/>
                    <measurement group_id="O3" value="-0.0" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=73,73,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="30.43"/>
                    <measurement group_id="O2" value="-1.4" spread="18.78"/>
                    <measurement group_id="O3" value="0.8" spread="18.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=63,52,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="35.83"/>
                    <measurement group_id="O2" value="1.3" spread="19.75"/>
                    <measurement group_id="O3" value="0.5" spread="17.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=111,123,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="24.91"/>
                    <measurement group_id="O2" value="-1.1" spread="19.06"/>
                    <measurement group_id="O3" value="-2.9" spread="18.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=94,111,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="23.85"/>
                    <measurement group_id="O2" value="-0.6" spread="28.07"/>
                    <measurement group_id="O3" value="-2.1" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=84,92,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="21.44"/>
                    <measurement group_id="O2" value="0.7" spread="28.81"/>
                    <measurement group_id="O3" value="-1.7" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=70,72,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="21.45"/>
                    <measurement group_id="O2" value="-0.5" spread="28.80"/>
                    <measurement group_id="O3" value="-4.0" spread="26.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=61,52,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="20.58"/>
                    <measurement group_id="O2" value="-0.6" spread="35.24"/>
                    <measurement group_id="O3" value="-5.3" spread="30.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=113,121,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="19.56"/>
                    <measurement group_id="O2" value="-8.7" spread="19.13"/>
                    <measurement group_id="O3" value="-5.4" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=96,109,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="20.64"/>
                    <measurement group_id="O2" value="-9.7" spread="23.25"/>
                    <measurement group_id="O3" value="-6.0" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=85,91,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="23.00"/>
                    <measurement group_id="O2" value="-7.1" spread="23.85"/>
                    <measurement group_id="O3" value="-5.4" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=72,73,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="25.91"/>
                    <measurement group_id="O2" value="-8.8" spread="24.90"/>
                    <measurement group_id="O3" value="-6.3" spread="21.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=62,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="23.87"/>
                    <measurement group_id="O2" value="-5.9" spread="25.79"/>
                    <measurement group_id="O3" value="-3.3" spread="20.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=113,120,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="13.37"/>
                    <measurement group_id="O2" value="0.1" spread="13.28"/>
                    <measurement group_id="O3" value="0.6" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=95,108,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="15.22"/>
                    <measurement group_id="O2" value="-1.7" spread="14.27"/>
                    <measurement group_id="O3" value="1.8" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=85,89,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="14.46"/>
                    <measurement group_id="O2" value="0.0" spread="15.99"/>
                    <measurement group_id="O3" value="0.3" spread="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=72,72,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="15.61"/>
                    <measurement group_id="O2" value="-1.0" spread="14.59"/>
                    <measurement group_id="O3" value="0.3" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=62,50,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="14.95"/>
                    <measurement group_id="O2" value="-2.9" spread="14.16"/>
                    <measurement group_id="O3" value="-0.9" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=112,121,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="23.74"/>
                    <measurement group_id="O2" value="4.3" spread="23.56"/>
                    <measurement group_id="O3" value="7.6" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=93,108,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="24.45"/>
                    <measurement group_id="O2" value="7.7" spread="23.86"/>
                    <measurement group_id="O3" value="9.8" spread="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=83,88,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="27.84"/>
                    <measurement group_id="O2" value="6.6" spread="22.40"/>
                    <measurement group_id="O3" value="14.5" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=71,73,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="27.15"/>
                    <measurement group_id="O2" value="6.3" spread="23.78"/>
                    <measurement group_id="O3" value="11.9" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=62,52,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="25.30"/>
                    <measurement group_id="O2" value="7.7" spread="28.49"/>
                    <measurement group_id="O3" value="14.4" spread="26.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale</title>
        <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.</description>
        <time_frame>Baseline (Day 0), Months 4, 7, 10, 13, 16</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>MPR+R</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O2">
            <title>MPR+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
          <group group_id="O3">
            <title>MPp+p</title>
            <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale</title>
          <description>Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 - approximately Month 4 (n=110,117,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="35.36"/>
                    <measurement group_id="O2" value="-0.3" spread="37.27"/>
                    <measurement group_id="O3" value="4.5" spread="25.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 - approximately Month 7 (n=88,104,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="33.32"/>
                    <measurement group_id="O2" value="2.6" spread="37.94"/>
                    <measurement group_id="O3" value="5.2" spread="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 - approximately Month 10 (n=79,83,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="33.32"/>
                    <measurement group_id="O2" value="-4.0" spread="43.69"/>
                    <measurement group_id="O3" value="3.9" spread="26.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 - approximately Month 13 (n=68,72,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="31.01"/>
                    <measurement group_id="O2" value="-0.5" spread="44.23"/>
                    <measurement group_id="O3" value="5.1" spread="32.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 - approximately Month 16 (n=59,52,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="32.58"/>
                    <measurement group_id="O2" value="6.4" spread="41.25"/>
                    <measurement group_id="O3" value="2.7" spread="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 169 weeks (Double-blind therapy period plus 4 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MPR+R</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="E2">
          <title>MPR+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
        <group group_id="E3">
          <title>MPp+p</title>
          <description>Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Norwalk virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Monoclonal immunoglobulin present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Oral intake reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Leukaemia plasmacytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Light chain disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Renal amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="951" subjects_affected="117" subjects_at_risk="150"/>
                <counts group_id="E2" events="807" subjects_affected="116" subjects_at_risk="152"/>
                <counts group_id="E3" events="398" subjects_affected="78" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="417" subjects_affected="99" subjects_at_risk="150"/>
                <counts group_id="E2" events="351" subjects_affected="91" subjects_at_risk="152"/>
                <counts group_id="E3" events="293" subjects_affected="82" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="514" subjects_affected="103" subjects_at_risk="150"/>
                <counts group_id="E2" events="532" subjects_affected="100" subjects_at_risk="152"/>
                <counts group_id="E3" events="268" subjects_affected="68" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="418" subjects_affected="54" subjects_at_risk="150"/>
                <counts group_id="E2" events="449" subjects_affected="58" subjects_at_risk="152"/>
                <counts group_id="E3" events="237" subjects_affected="49" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="25" subjects_affected="14" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="37" subjects_at_risk="150"/>
                <counts group_id="E2" events="66" subjects_affected="39" subjects_at_risk="152"/>
                <counts group_id="E3" events="93" subjects_affected="51" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="80" subjects_affected="49" subjects_at_risk="150"/>
                <counts group_id="E2" events="66" subjects_affected="39" subjects_at_risk="152"/>
                <counts group_id="E3" events="57" subjects_affected="37" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="124" subjects_affected="43" subjects_at_risk="150"/>
                <counts group_id="E2" events="62" subjects_affected="36" subjects_at_risk="152"/>
                <counts group_id="E3" events="50" subjects_affected="37" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="150"/>
                <counts group_id="E2" events="27" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E3" events="30" subjects_affected="19" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="150"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="110" subjects_affected="46" subjects_at_risk="150"/>
                <counts group_id="E2" events="97" subjects_affected="51" subjects_at_risk="152"/>
                <counts group_id="E3" events="101" subjects_affected="57" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="32" subjects_at_risk="150"/>
                <counts group_id="E2" events="63" subjects_affected="38" subjects_at_risk="152"/>
                <counts group_id="E3" events="33" subjects_affected="27" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="47" subjects_affected="30" subjects_at_risk="150"/>
                <counts group_id="E2" events="59" subjects_affected="35" subjects_at_risk="152"/>
                <counts group_id="E3" events="35" subjects_affected="25" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="33" subjects_at_risk="150"/>
                <counts group_id="E2" events="38" subjects_affected="22" subjects_at_risk="152"/>
                <counts group_id="E3" events="39" subjects_affected="25" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="150"/>
                <counts group_id="E2" events="32" subjects_affected="21" subjects_at_risk="152"/>
                <counts group_id="E3" events="34" subjects_affected="26" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="152"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" events="33" subjects_affected="17" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="24" subjects_at_risk="150"/>
                <counts group_id="E2" events="54" subjects_affected="36" subjects_at_risk="152"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" events="32" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="46" subjects_affected="17" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E2" events="23" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" events="18" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" events="25" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="96" subjects_affected="46" subjects_at_risk="150"/>
                <counts group_id="E2" events="77" subjects_affected="45" subjects_at_risk="152"/>
                <counts group_id="E3" events="76" subjects_affected="51" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E3" events="38" subjects_affected="29" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="20" subjects_at_risk="150"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E3" events="38" subjects_affected="21" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="152"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="34" subjects_affected="19" subjects_at_risk="150"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="150"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="150"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="150"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E3" events="35" subjects_affected="22" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="150"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="152"/>
                <counts group_id="E3" events="29" subjects_affected="21" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="150"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="62" subjects_affected="30" subjects_at_risk="150"/>
                <counts group_id="E2" events="63" subjects_affected="42" subjects_at_risk="152"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" events="23" subjects_affected="13" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgeneâs request, proposed publication or presentation will be delayed up to 90 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Trials Disclosure</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>1-888-260-1599</phone>
      <email>clinicaltrialdisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

